| Literature DB >> 32145207 |
Alex M Ebied1, Khushboo H Patel2, Rhonda M Cooper-DeHoff3.
Abstract
In 2019, the US Food and Drug Administration (FDA) approved 48 novel drugs. Thirty of the 48 (62.5%) novel drug approvals were reviewed and approved through an expedited review pathway while 20 of the 48 (41.7%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the FDA in 2019.Entities:
Keywords: Accelerated approval; Fast track; Food and Drug Administration (FDA); Novel drugs; Priority review
Year: 2020 PMID： 32145207 DOI： 10.1016/j.amjmed.2020.01.030
Source DB: PubMed Journal: Am J Med ISSN： 0002-9343 Impact factor: 4.965